Personal view: A potential novel treatment for fatigue complicating chronic liver disease - How should its efficacy be evaluated?

Alimentary Pharmacology and Therapeutics

Volumn 23, Issue 8, 2006, Pages 1113-1116

  Jones, E A ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

1 ISOPROPYL 6 METHYLERGOLINE 8 CARBOXYLIC ACID 2 HYDROXY 1 METHYLPROPYL ESTER; ONDANSETRON; PAROXETINE; PLACEBO; QUIPAZINE; SEROTONIN 3 ANTAGONIST; SEROTONIN AGONIST;

CHRONIC LIVER DISEASE; CLINICAL TRIAL; CONSTIPATION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; EXERCISE TOLERANCE; FATIGUE; HUMAN; LONG TERM CARE; NEUROTRANSMISSION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PRURITUS; QUANTITATIVE ANALYSIS; RATING SCALE; REVIEW; SCORING SYSTEM; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

FATIGUE; HEPATITIS C; HUMANS; LIVER CIRRHOSIS, BILIARY; LIVER DISEASES; ONDANSETRON; RANDOMIZED CONTROLLED TRIALS; SEROTONIN ANTAGONISTS; TREATMENT OUTCOME;

EID: 33646861634     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.02862.x     Document Type: Review

References (31)

1. Jones EA. Fatigue complicating chronic liver disease. Metab Brain Dis 2004 19 : 421 9.
2. Witt-Sullivan H Heathcote J Cauch K, et al. The demography of primary biliary cirrhosis in Ontario, Canada. Hepatology 1990 12 : 98 105.
3. Cauch-Dudek K Abbey S Stewart DE Heathcote EJ. Fatigue in primary biliary cirrhosis. Gut 1998 43 : 705 10.
4. Wessely S Pariante C. Fatigue, depression and chronic hepatitis C. Psychol Med 2002 32 : 1 10.
5. Bailey SP Davis JM Ahlborn EN. Neuroendocrine and substrate responses to altered brain 5-HT activity during prolonged exercise to fatigue. J Appl Physiol 1993 74 : 3006 12.
6. Wilson WM Maughan RJ. Evidence for a possible role of 5-hydroxy-tryptamine in the genesis of fatigue in man: administration of paroxetine, a 5-HT re-uptake inhibitor, reduces the capacity to perform prolonged exercise. Exp Physiol 1992 77 : 921 4.
7. Jones EA. Fatigue associated with chronic liver disease: a riddle wrapped in a mystery inside an enigma. Hepatology 1995 22 : 1606 8.
8. Jones EA Yurdaydin C. Is fatigue associated with cholestasis mediated by altered central neurotransmission Hepatology 1997 25 : 492 4.
9. Jones EA. Altered central serotoninergic neurotransmission: A potential mechanism for profound fatigue complicating chronic hepatitis C. Med Hypotheses 2001 57 : 133 4.
10. Jones EA. Relief from profound fatigue associated with chronic liver disease by long-term ondansetron therapy. Lancet 1999 354 : 397.
11. Theal JJ Toosi MN Girlan L, et al. A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue. Hepatology 2005 41 : 1305 12.
12. Schwartz JE Jandorf L Krupp LB. The measurement of fatigue: a new instrument. J Psychosom Res 1993 37 : 753 62.
13. Fisk JD Ritvo PG Ross L Haase DA Marrie TJ Schlech WF. Measuring the functional impact of fatigue: initial validation of the Fatigue Impact Scale. Clin Infect Dis 1994 18 Suppl S79 83.
14. Elkins LE Krupp LB Scherl W. The measurement of fatigue and contributing neuropsychiatric factors. Semin Clin Neuropsychol 2000 5 : 58 61.
15. Kleinman L Zodat MW Hakim Z Aledort J Barker C Chank D. Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C. Qual Life Res 2000 9 : 499 508.
16. Prince MI James OF Holland NP Jones DE. Validation of a fatigue impact score in primary biliary cirrhosis: Towards a standard for clinical and trial use. J Hepatol 2000 32 : 368 73.
17. McCormack HM de L'Horne DJ Sheather S. Clinical applications of visual analogue scales: a critical review. Psychol Med 1988 18 : 1007 19.
18. Jones EA. Trials of opiate antagonists for the pruritus of cholestasis: primary efficacy endpoints and opioid withdrawal-like reactions. J Hepatol 2002 37 : 864 5.
19. Talbot TL Schmitt JM Bergasa NV Jones EA Walker EC. Application of piezofilm technology for the quantitative assessment of pruritus. Biomed Instrum Technol 1991 25 : 400 3.
20. Molenaar HAJ Oosting J Jones EA. Improved device for measuring scratching activity in patients with pruritus. Med Biol Eng Comput 1998 36 : 220 4.
21. Bergasa NV Talbot TL Alling DW, et al. A controlled trial of naloxone infusions for the pruritus of cholestasis. Gastroenterology 1992 102 : 544 9.
22. Bergasa NV Alling DW Talbot TL, et al. Effects of naloxone infusions in patients with the pruritus of cholestasis: a double-blind randomized controlled trial. Ann Intern Med 1995 123 : 161 7.
23. Bergasa NV Schmitt JM Talbot TL, et al. Open label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology 1998 27 : 679 84.
24. Bergasa NV Alling DW Talbot TL Wells MC Jones EA. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study. J Am Acad Dermatol 1999 41 : 431 4.
25. Bruce RA. Exercise testing of patients with coronary disease. Principles and normal standards for evaluation. Ann Clin Res 1971 3 : 323 32.
26. Jalan R Gibson H Lombard MG. Patients with PBC have central but not peripheral fatigue. Gut 1996 39 Suppl. 1 A30.
27. Goldblatt J James OF Jones DE. Grip strength and subjective fatigue in patients with primary biliary cirrhosis. J Am Med Assoc 2001 285 : 2196 7.
28. Feinstein AR. An additional basic science for clinical medicine: II. The limitations of randomized trials. Ann Intern Med 1983 99 : 544 50.
29. Le Fanu J. Twelve defining moments. Looking to the future. In : The Rise and Fall of Modern Medicine. London : Little, Brown and Company, 1999 : 57 406 7
30. Goldman GM. The tacit dimension of clinical judgement. Yale J Biol Med 1990 63 : 47 61.
31. Tanenbaum SJ. What physicians know. N Engl J Med 1993 329 : 1268 71.